12 May 2020 | News
In cooperation with Lilly China
Image credit- shutterstock.com
111, Inc., a leading integrated online and offline healthcare platform in China, has announced that it is launching a new diabetes patient management platform in cooperation with Lilly China.
The two companies will work together to build a comprehensive diabetes patient management platform that includes services such as disease management, disease education and patient support programs to enrich patients' knowledge of chronic disease management and to better help diabetic patients to self-manage from home. The platform will seek to harness the power of internet hospital technologies, big data and artificial intelligence technologies to provide diabetic patients with a comprehensive digital health management solution.
111 has accumulated extensive experience in operations management in the area of chronic disease, especially in diabetes, laying a solid foundation for the development of the diabetes management platform. With the transformative power of technology, the platform will seek to provide patients with a one-stop solution for "physician consultation + medication" services, allowing patients to consult with qualified physicians online, and receive personalized healthcare management services, online refill service, and medication delivery services.
As the first multinational pharmaceutical company to join the platform, Lilly China will leverage its expertise in the field of diabetes management and will also offer a variety of patient management and support programs, including "Lilly Connected Care Program" and Patient Benefit Program, to eligible diabetes patients, with the aim of providing personalized disease education and health management services. In addition, with its deep experience in the diabetes field, Lilly China will help to develop a directory of disease education resources to help patients understand risk factors, signs and symptoms, and treatment options.